The study will evaluate most commonly used medical strains and the ailments they are best suited to treat

TORONTO, Mar. 2, 2016 /CNW/ - Mettrum Health Corp. ("Mettrum" or the "Company") (TSXV:MT), a vertically integrated licensed producer (LP) of cannabis products, this week launched the Mettrum Registry Research Program (MRRP) to systematically gather data on up to six thousand Canadian patients who have been prescribed medical cannabis.

The goal of this observational study is to provide information to prescribing physicians and the wider medical community to help determine if and how cannabis should be prescribed – focusing on which strains best suit a particular patient's needs. It also considers the impact of intercurrent illness or potential interactions with other medications. The study will run for one year, with results anticipated to be published by March 2017.

"Our motivation for conducting this research is to ensure that individuals who are prescribed Mettrum Dried Cannabis or Cannabis oils, are able to receive the full potential of their prescription," said Michael Haines, CEO of Mettrum. "We believe the data gathered will generate a greater understanding of the factors that influence how medical cannabis is and should be prescribed. This includes which medical strains are most commonly used and the medical conditions and symptoms they most effectively address. We also hope to determine how the effects of medical cannabis might be modified by other conditions an individual has, or by other medications they might be taking concurrently."

Through this research, Mettrum will be collecting information relating to target conditions and/or symptoms, the presence of other diseases, patient demographics and other medications that these patients are actively taking along with the strain or strains the patient is using to treat the medical condition and symptoms. In addition, Mettrum will collect feedback from physicians on the effectiveness of the cannabis treatment.

Beginning in March, physicians will opt-in to the MRRP online, via the Mettrum Cannabis Electronic Medical Records (CEMR) application. The CEMR allows for the creation and secure electronic transmission of prescriptions and related patient registration documents, as well as physician-only access to resource materials, literature and the data from the study. The CEMR is also the data collection platform for the MRRP.

The MRRP has been submitted and approved by the Canadian SHIELD Ethics Review Board (www.cserb.com), and all patient and prescribing physician information is protected. Any communication or publications arising from this research will be described in aggregate form, safeguarding the identity of the study participants.

Mettrum is currently recruiting physicians interested in becoming study investigators in this exciting and important initiative. If you would like to learn more about the Mettrum Registry Research Program, please contact Mettrum at 1-866-920-2009 or send an email to [email protected].

About Mettrum Health Corp

Mettrum Health Corp. is a Tier-1 Industry Issuer listed on TSX Venture Exchange. Mettrum Ltd., a wholly owned subsidiary, is a Toronto-based company and licensed producer of medical cannabis under the Marihuana for Medical Purposes Regulations (Canada) (MMPR) issued pursuant to the Controlled Drugs and Substances Act (Canada). The Company is a leading producer and vendor of medical cannabis under the MMPR system and has three licensed production facilities totalling 85,000 square feet representing annual production capacity of approximately 12,000 kilograms.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the results of operations. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company and Mettrum disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this Press release.

SOURCE Mettrum Health Corp.

For further information: Joanne D'Souza, Argyle Public Relationships, 416-968-7311 x236, [email protected]